Board of Directors

Bard Geesaman

Bard Geesaman, M.D., Ph.D.

Board Member
Bard Geesaman, M.D., Ph.D., was affiliated with MPM and associated portfolio companies from 2002-2018. With broad experience investing, operating and facilitating business development globally, including in Japan, China and Israel, Bard was a Managing Director of MPM’s Oncology Impact Fund (OIF) and served on multiple boards.

Prior to MPM, Bard founded Catalyst Medical Solutions, a medical documentation and billing eHealth company in Boston where he served as the Chief Technology Officer through the company’s acquisition. After Catalyst, Bard joined Centagenetix, an MPM-founded company exploring the genetics of successful aging.

In 2006, Bard joined MPM as a Venture Partner with a major focus on founding Solasia Pharmaceuticals, based in Tokyo, Japan. Bard is also the co-founder and a board member of MPM healthcare IT startup TriNetX (big data analytics for clinical trials). Bard is passionate about innovation in health care, and in 2008 took a two year sabbatical from MPM to do non-profit work in Los Angeles at the X-Prize Foundation, where he worked on alternative models for motivating life sciences innovation.

He received a BS in neuroscience from UC Berkeley followed by concurrent degrees from Harvard Medical School and the Massachusetts Institute of Technology., with his PhD work focused on systems and computational neurobiology. Bard finished his medical training by completing a three-year medical residency at Massachusetts General Hospital.

Leslie Henshaw

Leslie Henshaw

Board Member
As a Partner on the Private Transactions team at Deerfield, Leslie works with a variety of healthcare services and healthcare information technology companies that are both current and potential investment partners. Before joining Deerfield in 2005, Leslie was co-manager of an ING branded healthcare hedge fund she launched in 2000. Prior to that she spent 11 years in the investment banking, high yield research and equity research departments at Furman Selz and ING, where she focused exclusively on companies in the healthcare arena. In these roles Leslie developed wide ranging experience in executing M&A transactions, structuring debt and equity financings for both public and private companies and analyzing company potential through the lens of public investors. She also spent two years as a member of the national healthcare consulting practice of Price Waterhouse. Leslie graduated with High Honors from Wesleyan University, and she earned her M.B.A. from the University of Chicago.  She currently serves on the Board of Directors of five Deerfield portfolio companies.

Morana Jovan-Embiricos, PhD

Morana Jovan-Embiricos, PhD

Board Member
Dr. Jovan-Embiricos is the founder of F2 Ventures. She has extensive experience in both the public and private biotechnology equity markets through a series of funds launched at F2 since 2003. She also successfully managed a biotech allocation for one of the largest hedge funds in the USA. Prior to F2, Dr. Jovan-Embiricos was a Partner with MPM Capital working both on the investment side and directly with portfolio companies to help them attain critical business development milestones and securing appropriate exits either through trade sale or an IPO. She also led life sciences activities at Banque Syz & Co in Geneva, launching one of the first long only biotech funds in Switzerland. Dr. Jovan-Embiricos is also a member of the Board of Damon Runyon Cancer Research Foundation. She holds an Executive Business Program from Stanford-National University of Singapore and was a post-doctoral fellow at Harvard University having worked on protein un-caging in the Department of Developmental Biology. She received her PhD in Biophysical Chemistry from the University of Cambridge.

Gadi Lachman

Board Member
Gadi Lachman previously held leadership positions at TriZetto, American Well and Eliza. He was also at Lehman Brothers and was an Officer in Israeli Special Forces. Gadi earned his MBA at Harvard Business School, and his LLB in law and B.C. in accounting from Tel-Aviv University.

Jeff Margolis

Jeff Margolis

Board Member
Jeff Margolis is widely recognized as a healthcare IT entrepreneur and innovator based on his 30-year track record of successfully applying technologies to address the complex problems facing the healthcare industry. Leveraging his deep systematic understanding of healthcare and groundbreaking architectural and integration methodologies, Jeff has built some of the nation’s largest and most innovative healthcare technology and service organizations. Jeff is currently Chairman and CEO of Welltok, Inc., where he is driving the transformation of our current sickcare system to one of optimized health. Prior to Welltok, Jeff founded TriZetto, the first industry vertical SaaS enterprise solution, and originated the concept of Integrated Healthcare Management. During his tenure as Chairman and CEO, Jeff led TriZetto through a successful IPO and $1.4B private equity buyout. Jeff currently serves as a member of the board of directors for Quality Systems, Inc. (NASDAQ:QSII), Alignment Healthcare and TriNetX. Jeff also serves the national and local communities on the boards of several prominent non-profit and for profit organizations, including Hoag Hospital in Newport Beach and the University of California at Irvine Center for Digital Transformation. As a health futurist and visionary, Jeff is a frequent speaker, guest lecturer and author of two books, including The Healthcare Cure. Jeff is an alumnus of the University of Illinois and holds certified public accountant certificates in Colorado and Illinois.

Tony Rosenberg

Tony Rosenberg

Board Member
Tony Rosenberg joined MPM in 2015. Prior to joining MPM, Tony served as Global Head, M&A and Licensing (Corporate) for Novartis (NVS), based in Basel, Switzerland. In this role Tony oversaw the Novartis portfolio transformation, a comprehensive set of transactions announced in 2014 to focus Novartis on its global businesses in innovative pharmaceuticals, eye care and generics. Tony is a Board member at argenx BV, Iomx AG, Oculis SA, Radius and TriNetX. Tony joined Novartis predecessor company Sandoz in the U.K. in 1980, where he held diverse leadership positions across sales and marketing, business development and strategic planning. He moved to Basel in 1994, assuming roles of increasing responsibility, and in 2000 was appointed Global Head of the Transplantation and Immunology Business Unit. In 2005, Tony was appointed Global Head of Business Development and Licensing (Pharma), and managed over 30 major in-licensing transactions across therapeutic areas as well as numerous divestments. In 2010, he assumed added responsibility leading the Molecular Diagnostics Group. Tony has a Bachelor of Science degree in Biological Sciences from the University of Leicester and a Masters of Science in Physiology from the University of London.

Joe Volpe

Joseph B Volpe

Board Member
Joe has more than two decades of experience in health care investing applying a technical engineering background coupled with an understanding of emerging technologies.  He is considered to be one of the industry’s leading corporate investors.  In 2016, Joe was named by Global Corporate Venturing as one of the top five rising stars.

Joe currently holds board seats with TriNetX, Prognos, Preventice, ClearDATA and Exostar.  Previously he sat on the boards with Koneksa, Mihealth and exited Aptus Health and Liaison. Joe was observer on Humedica and Healthsense. Joe chairs several M&A and Audit committee positions while holding current board seats.

Colleagues have called Joe instrumental in transforming Merck GHIF from a leader, not only in venture capital, but also in growth equity and M&A.  He earned industry laurels when he participated in the sale of Humedica, a healthcare analytics company, to UnitedHealth Group in 2013, a transaction that produced a 17-fold return.

In addition to his success with Humedica, Joe has led investments and acquisitions in companies such as TriNetX, Liaison, Preventice, Physicians Interactive, Koneksa, Prognos, WellDoc, Exostar, Milheath and ClearDATA.  He has evaluated thousands of digital health companies and has invested in two to three companies annually since 2011.  During that same period, he has also managed 50-plus transactions at Merck, all at various stages of maturity.

Another notable success for Joe was his leadership with Preventice to further develop its remote care monitoring platform for cardiac arrhythmia patients.  Joe led the Merck strategy and merger of Preventice with eCardio and eventually sold a portion of the combined company to a leading healthcare channel partner, which paid back the fund for the original investment while maintaining majority share of a more valued company.  Joe also focused on the patient physician engagement space with his Physicians Interactive (now called Aptus) investments.  He eventually led the acquisition of the company on behalf of Merck GHIF.  Joe also led the acquisitions of MedHelp, Quantia MD and Tomorrow Networks within Aptus.

Joe came to Merck from Johnson and Johnson where he spent more than 20 years in innovation and investment roles across Consumer, Pharma and Device sectors of J&J.  Prior to that he was a consultant with EDS where he was selected and graduated from their Top Gun business and technology program.  He went to the University of South Florida where he obtained a degree in Business/Information Systems and Engineering.